BioSpace News Archive

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated the efficacy and safety of vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

PAO Group, Inc. (USOTC: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).

Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, today announces the completion of the acquisition of Holo Surgical Inc., (‘Holosurgical’), a Chicago-based private technology company developing the revolutionary Augmented Reality and Artificial Intelligence platform (‘ARAI™’).

CVS Health Corporation will hold a conference call with analysts and investors on Friday, November 6, 2020, at 8:00 a.m. to discuss its financial results for the third quarter of 2020.

Laparoscopy is a surgical technique that is utilized to enter into body cavities with minimal external cuts and intrusions.

According to Transparency Market Research’s latest report on the global durable medical equipment market for the historical period 2017–2018 and forecast period 2019–2027, increasing number of people with one or more disabilities, rising government initiatives in preventive health care programs are projected to drive the global durable medical equipment market during the forecast period

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it will host a virtual R&D Day on 06 November 2020 from 13.00 CET.

The Action Network gives advocates tangible actions they can take to raise awareness and engage in policy for people affected by lung cancer

CV Sciences, Inc., a preeminent supplier and manufacturer of hemp cannabidiol products, announced that it will release financial results for the third quarter ended September 30, 2020, after the stock market closes on Thursday, November 5, 2020.

Milestone Pharmaceuticals Inc. announced the pricing of its previously announced underwritten public offering of 3,810,097 of its common shares, and to certain investors in lieu thereof, pre-funded warrants to purchase 4,761,903 of its common shares at an exercise price of $0.01 per share.